FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078164029> ?p ?o ?g. }

• W2078164029 endingPage "483" @default.
• W2078164029 startingPage "472" @default.
• W2078164029 abstract "Tumor vaccine after high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) aims at directing immune recovery toward tumor responses after optimizing minimal residual disease. We have characterized T-cell recovery and tumor response after a regimen devised as a platform for such immunotherapy. One hundred patients with high-risk or metastatic breast cancer received 3 to 7 cycles of paclitaxel and cyclophosphamide (overall response rate, 78%) and then HDC with melphalan and etoposide. Seventy-one patients received HDC and ASCT (no mortality at 100 days). At 24 months after transplantation, progression-free and overall survival probabilities for patients with stage IIIA, IIIB, and IV disease were 82%, 81%, and 42% and 100%, 94%, and 68%, respectively. The median progression-free and overall survivals from entry on study for stage IV patients were 15.3 and 38.1 months, respectively. CD3 + , CD8 + , and CD4 + cells were severely depleted after ASCT. Although total CD8 + T-cell numbers approached the normal range by 3 months, most of these cells were CD28 - . Naive CD45RA + CD4 + T cells approached the normal range only 18 months after ASCT and only in younger patients. The described observations provide the basis for devising a strategy for cancer vaccine administration after ASCT. Incorporating immune reconstitution enhancement after ASCT may be advantageous." @default.
• W2078164029 created "2016-06-24" @default.
• W2078164029 creator A5003847273 @default.
• W2078164029 creator A5007978312 @default.
• W2078164029 creator A5011431831 @default.
• W2078164029 creator A5023659191 @default.
• W2078164029 creator A5042150016 @default.
• W2078164029 creator A5044239219 @default.
• W2078164029 creator A5062706815 @default.
• W2078164029 creator A5063126623 @default.
• W2078164029 creator A5064376671 @default.
• W2078164029 creator A5064465715 @default.
• W2078164029 creator A5066218992 @default.
• W2078164029 creator A5074220802 @default.
• W2078164029 creator A5074691355 @default.
• W2078164029 creator A5083522277 @default.
• W2078164029 creator A5089893290 @default.
• W2078164029 date "2005-06-01" @default.
• W2078164029 modified "2023-10-15" @default.
• W2078164029 title "Establishing a Platform for Immunotherapy: Clinical Outcome and Study of Immune Reconstitution after High-Dose Chemotherapy with Progenitor Cell Support in Breast Cancer Patients" @default.
• W2078164029 cites W118686632 @default.
• W2078164029 cites W1481612531 @default.
• W2078164029 cites W1483173437 @default.
• W2078164029 cites W1602332889 @default.
• W2078164029 cites W1890813079 @default.
• W2078164029 cites W1942361359 @default.
• W2078164029 cites W1973560717 @default.
• W2078164029 cites W1973702706 @default.
• W2078164029 cites W2014779265 @default.
• W2078164029 cites W2053824166 @default.
• W2078164029 cites W2083616014 @default.
• W2078164029 cites W2099070927 @default.
• W2078164029 cites W2108238886 @default.
• W2078164029 cites W2110289042 @default.
• W2078164029 cites W2115293064 @default.
• W2078164029 cites W2118884723 @default.
• W2078164029 cites W2151246207 @default.
• W2078164029 cites W2230845873 @default.
• W2078164029 cites W4248626267 @default.
• W2078164029 cites W4250218811 @default.
• W2078164029 cites W4293241248 @default.
• W2078164029 doi "https://doi.org/10.1016/j.bbmt.2005.03.010" @default.
• W2078164029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15931636" @default.
• W2078164029 hasPublicationYear "2005" @default.
• W2078164029 type Work @default.
• W2078164029 sameAs 2078164029 @default.
• W2078164029 citedByCount "16" @default.
• W2078164029 countsByYear W20781640292013 @default.
• W2078164029 countsByYear W20781640292018 @default.
• W2078164029 countsByYear W20781640292020 @default.
• W2078164029 countsByYear W20781640292021 @default.
• W2078164029 crossrefType "journal-article" @default.
• W2078164029 hasAuthorship W2078164029A5003847273 @default.
• W2078164029 hasAuthorship W2078164029A5007978312 @default.
• W2078164029 hasAuthorship W2078164029A5011431831 @default.
• W2078164029 hasAuthorship W2078164029A5023659191 @default.
• W2078164029 hasAuthorship W2078164029A5042150016 @default.
• W2078164029 hasAuthorship W2078164029A5044239219 @default.
• W2078164029 hasAuthorship W2078164029A5062706815 @default.
• W2078164029 hasAuthorship W2078164029A5063126623 @default.
• W2078164029 hasAuthorship W2078164029A5064376671 @default.
• W2078164029 hasAuthorship W2078164029A5064465715 @default.
• W2078164029 hasAuthorship W2078164029A5066218992 @default.
• W2078164029 hasAuthorship W2078164029A5074220802 @default.
• W2078164029 hasAuthorship W2078164029A5074691355 @default.
• W2078164029 hasAuthorship W2078164029A5083522277 @default.
• W2078164029 hasAuthorship W2078164029A5089893290 @default.
• W2078164029 hasBestOaLocation W20781640291 @default.
• W2078164029 hasConcept C121608353 @default.
• W2078164029 hasConcept C126322002 @default.
• W2078164029 hasConcept C143998085 @default.
• W2078164029 hasConcept C167672396 @default.
• W2078164029 hasConcept C203014093 @default.
• W2078164029 hasConcept C2776694085 @default.
• W2078164029 hasConcept C2776755627 @default.
• W2078164029 hasConcept C2777701055 @default.
• W2078164029 hasConcept C2778119113 @default.
• W2078164029 hasConcept C2778684742 @default.
• W2078164029 hasConcept C2779050716 @default.
• W2078164029 hasConcept C2781413609 @default.
• W2078164029 hasConcept C530470458 @default.
• W2078164029 hasConcept C71924100 @default.
• W2078164029 hasConcept C8891405 @default.
• W2078164029 hasConceptScore W2078164029C121608353 @default.
• W2078164029 hasConceptScore W2078164029C126322002 @default.
• W2078164029 hasConceptScore W2078164029C143998085 @default.
• W2078164029 hasConceptScore W2078164029C167672396 @default.
• W2078164029 hasConceptScore W2078164029C203014093 @default.
• W2078164029 hasConceptScore W2078164029C2776694085 @default.
• W2078164029 hasConceptScore W2078164029C2776755627 @default.
• W2078164029 hasConceptScore W2078164029C2777701055 @default.
• W2078164029 hasConceptScore W2078164029C2778119113 @default.
• W2078164029 hasConceptScore W2078164029C2778684742 @default.
• W2078164029 hasConceptScore W2078164029C2779050716 @default.
• W2078164029 hasConceptScore W2078164029C2781413609 @default.
• W2078164029 hasConceptScore W2078164029C530470458 @default.
• W2078164029 hasConceptScore W2078164029C71924100 @default.
• W2078164029 hasConceptScore W2078164029C8891405 @default.

• next